Kubota, Takeshi, Jidong Fang, Tetsuya Kushikata, and James M. Krueger. Interleukin-13 and transforming growth factor-␤1 inhibit spontaneous sleep in rabbits. Am J Physiol Regulatory Integrative Comp Physiol 279: R786-R792, 2000.-Proinflammatory cytokines, including interleukin-1␤ and tumor necrosis factor-␣ are involved in physiological sleep regulation. Interleukin (IL)-13 and transforming growth factor (TGF)-␤1 are anti-inflammatory cytokines that inhibit proinflammatory cytokines by several mechanisms. Therefore, we hypothesized that IL-13 and TGF-␤1 could attenuate sleep in rabbits. Three doses of 40, and 200 ng) and TGF-␤1 (40, 100, and 200 ng) were injected intracerebroventricularly 3 h after the beginning of the light period. In addition, one dose of IL-13 (200 ng) and one dose of TGF-␤1 (200 ng) were injected at dark onset. The two higher doses of IL-13 and the highest dose of TGF-␤1 significantly inhibited spontanenous non-rapid eye movement sleep (NREMS) when they were given in the light period. IL-13 also inhibited NREMS after dark onset administration; however, the inhibitory effect was less potent than that observed after light period administration. The 40-ng dose of IL-13 inhibited REMS duration during the dark period. TGF-␤1 administered at dark onset had no effect on sleep. These data provide additional evidence for the hypothesis that a brain cytokine network is involved in regulation of physiological sleep.
IL-13 is considered to be an important macrophagedeactivating factor. IL-13 shares many of its biological functions with IL-4. They have a 20-25% homology in their amino acid structure. Moreover, IL-13 and IL-4 receptors involve a common component, IL-4R␣ (reviewed in 3). IL-13 suppresses IL-1␤ and TNF-␣ production in vitro (5, 9, 61) . Some in vivo studies also demonstrate that IL-13 inhibits LPS-induced TNF-␣ and IL-1␤ production in mice (10, 34) . Moreover, IL-13 promotes the production of additional anti-inflammatory substances including the IL-1 receptor antagonist (9, 33, 59, 61) and the IL-1 type II receptor (4) .
TGF-␤1 is an important regulator of immune and inflammatory processes in the central nervous system (CNS) (reviewed in Ref. 30) . TGF-␤1 is part of a complex network that forms a negative-feedback system for IL-1 and TNF-␣ production (43) . IL-1 stimulates TGF-␤1 expression in glial cells (7) . Conversely, TGF-␤1 suppresses microglial activation, proliferation, and IL-1␤ and TNF-␣ production (47) . TGF-␤1 also inhibits IL-1␤-induced cellular inflammation in the retina (6) . Furthermore, TGF-␤ receptor mRNAs and proteins are present in the CNS (60) .
These findings suggest that IL-13 and TGF-␤1 could modulate endogenous sleep regulatory substances and, thereby, affect sleep. We report here that IL-13 and TGF-␤1 inhibit rabbit NREMS without affecting brain temperature (Tbr) and electroencephalographic (EEG) slow-wave activity (SWA).
MATERIALS AND METHODS
Agents. Recombinant human IL-13 and TGF-␤1 were purchased from R&D Systems (Minneapolis, MN). IL-13 was dissolved in pyrogen-free isotonic NaCl (PFS; Abbott Laboratories, North Chicago, IL) at the concentrations of 8, 40, and 200 ng in volumes of 25 l. TGF-␤1 was dissolved in 25 l PFS at the doses of 40, 100, and 200 ng. They were stored under sterile conditions at Ϫ80°C until the experiment.
Animals. Male New Zealand White Pasteurella-free rabbits weighing 3.5-4.5 kg were surgically implanted with EEG electrodes, a brain thermistor, and a lateral intracerebroventricular cannula under ketamine-xylazine anesthesia as previously described (26, 27) . Briefly, the guide cannula was placed in the left lateral ventricle for intracerebroven-tricular injection. A calibrated 30-k⍀ thermistor (model 44008; Omega Engineering, Stamford, CT) was implanted on the dura mater over the parietal cortex to measure Tbr. The leads from the electrodes and the thermistor were routed to a Teflon pedestal. The pedestal, guide cannula, and leads were attached to the skull with dental acrylic (Duz-All; Coralite Dental Products, Skokie, IL). After at least 2 wk of recovery, the animals were placed in experimental chambers (Hot Pack 352600, Philadelphia, PA). The animals were kept on a 12:12-h light-dark cycle (0600 light on) at 21 Ϯ 1°C ambient temperature. Water and food were ad libitum throughout the experiment.
Recording and analysis. A flexible tether connecting the EEG electrodes and the thermistor was led to an electronic swivel (SL6C, Plastics One, Roanoke, VA). Body movements were detected by ultrasonic detectors (Biochemical Instrumentation, University of Tennessee). The leads from the swivel and movement detectors were routed to Grass model 7D polygraphs in an adjacent room. The EEG was filtered below 0.1 Hz and above 35 Hz. The amplified signals were digitized at the frequency of 128 Hz for the EEG and at 2 Hz for Tbr and motor activity. Tbr data were saved on a computer in 10-s intervals. The vigilance states of wakefulness, NREMS and rapid eye movement sleep (REMS) were visually determined offline in 10-s epochs by using criteria previously reported (26, 27) . In brief, wakefulness was characterized by fast low-amplitude EEG waves, gradually increasing Tbr, and a high incidence of gross body movements. NREMS was associated with slow high-amplitude EEG waves, slowly decreasing Tbr, and lack of body movements. In contrast, REMS was characterized by fast lowamplitude EEG waves, appearance of theta activity in the EEG, rapidly increasing Tbr at REMS onset, and a lack of body movement. Online Fourier analysis of the EEG was performed. The average of EEG power density in the delta frequency band (0.5-4.0 Hz) during NREMS, also called EEG SWA, was calculated. The average power of EEG SWA throughout the entire 23-h control recording period was normalized to 100% for each animal. Then all EEG SWA data were expressed as a percentage of that control value. The average amount of time spent in each vigilance state, EEG SWA, and Tbr were calculated for 2-h intervals for purposes of graphic display ( Figs. 1 and 2 ). In addition, the number of NREMS and REMS episodes, the mean episode length, and mean length of sleep cycles (R-R interval: time between the onset of a REMS episode and the onset of the next REMS episode) were determined using a computer program with the criterion that each REMS episode lasted at least 30 s.
Experimental protocols. Each rabbit was injected with 25 l PFS intracerebroventricularly on a separate control day. If a rabbit was used more than once, at least 7 days separated the injections, and a separate control day recording was obtained. In experiment 1, 12 rabbits were used. Rabbits received one to three doses of IL-13 during the light period: 8 (n ϭ 7), 40 (n ϭ 8), and 200 ng (n ϭ 8). Injections took place between 0845 and 0915. Eight rabbits received 200 ng of IL-13 at dark onset (1800). In experiment 2, a different set of 12 rabbits was used. Rabbits were injected with one to three doses of TGF-␤1 during light period (0845-0915): 40 (n ϭ 8), 100 (n ϭ 7), and 200 ng (n ϭ 8) on the experimental day. Nine rabbits received 200 ng of TGF-␤1 at dark onset (1800). After injections, EEG, Tbr, and motor activity were recorded for the next 23 h.
Statistical analysis. Two-way ANOVA for repeated measures followed by a Student-Newman-Keuls test was used to analyze data concerning time spent at each vigilance state, EEG SWA, and Tbr; 3-h time blocks were used for these analyses. For the sleep-episode data, one-way ANOVA for repeated measures was used for the entire 23-h period, the 9-h light period between the time of injection and the dark period, and the 12-h dark period. A significance level of P Ͻ 0.05 was accepted.
RESULTS

Experiment 1: effects of IL-13 on spontaneous sleep in rabbits.
The lowest dose of IL-13, 8 ng, failed to affect any of the sleep parameters measured (Table 1 ). In contrast, the two higher doses of IL-13 administered during the light period significantly inhibited NREMS [ANOVA treatment effects for the entire 23-h postinjection period: 40 ng, F(1,7) ϭ 15.79, P ϭ 0.0054; 200 ng, F(1,7) ϭ 7.04, P ϭ 0.0325; ANOVA treatment effects for the 12-h dark period: 40 ng, F(1,7) ϭ 11.61, P ϭ 0.0113; 200 ng, F(1,7) ϭ 7.28, P ϭ 0.0307; Table 1 and Fig. 1 ]. The NREMS inhibitory effect during the dark period was due to a decrease in the number of NREMS episodes [ANOVA for the 12-h dark period: 200 ng, F(1,7) ϭ 9.70, P ϭ 0.0170; Table 2 ]. The decreases in NREMS during the initial 9-h light period did not reach significance after any dose. The 200-ng dose given at dark onset also inhibited NREMS; however, it was less effective than the same dose given during the light period [ANOVA treatment effects for the 23-h postinjection period: F(1,7) ϭ 17.36, P ϭ 0.0042; Table 1 and Fig. 1 ]. This effect was also due to a decrease in the number of NREMS episodes [ANOVA for 23 h: F(1,7) ϭ 6.35, P ϭ 0.0398; Table 2 ]. REMS was inhibited during the dark period after the 40-ng dose of IL-13 [ANOVA for the 12-h dark period: F(1,7) ϭ 9.94, P ϭ 0.0161], and it was due to a decrease in the number of REMS episodes [ANOVA for 12 h: F(1,7) ϭ 13.5, P ϭ 0.0080]. As a result, a significant increase in the sleepcycle length (R-R interval) was observed [ANOVA for 23 h: F(1,7) ϭ 5.80, P ϭ 0.0469; Tables 1 and 3] . Although a significant decrease in the total amount of time in REMS was not found after 200 ng of IL-13 administration at dark onset, the number of REMS episodes during the dark period was significantly inhibited [ANOVA for the 12-h dark period: F(1,7) ϭ 9.21, P ϭ 0.0188; Table 3 ]. EEG SWA and Tbr were not affected by any of the IL-13 doses tested. Furthermore, IL-13 did not induce gross abnormal behavior; animals appeared normal when handled, and no motor abnormalities were evident. Table 1 ]. REMS, EEG SWA, and Tbr were not affected by any of the TGF-␤1 doses given. Furthermore, abnormal behavior was not observed after any dose of TGF-␤1.
DISCUSSION
The major finding in the present study is that both IL-13 and TGF-␤1 inhibit NREMS. These effects are similar to those we previously reported for IL-4 and IL-10 (26, 27). These inhibitory actions are likely due to inhibition of production of endogenous sleep regulatory substances such as IL-1␤, TNF-␣, and nitric oxide (NO). IL-13 (5, 9, 10, 34, 61) and TGF-␤1 (47) suppress IL-1␤ and TNF-␣ production. They inhibit the expres- Values are means Ϯ SE; n, no. of rabbits. Sleep data are expressed as the time spent in non-rapid eye movement sleep (NREMS) or rapid eye movement sleep (REMS) for each time period. For electroencephalographic slow-wave activity (SWA) data, the average power during NREMS throughout the 23-h control recording period in each rabbit was normalized to 100%. Then a relative value from the control recording was calculated. Brain temperatures (Tbr) are expressed as mean values collected in 10-s intervals for 23-h entire period. Light period data include initial 9 h data after the injection at 0900 or 11 h data following 12-h dark period after the injection at 1800. * P Ͻ 0.05 vs. vehicle treatment. IL-13, interleukin-13; TGF-␤1, transforming growth factor-␤1. Values are means Ϯ SE. The number and length of the episodes were determined using a computer program with the criterion that each episode lasted at least 30 s. Light period data include initial 9 h data after the injection at 0900 or 11 h data following 12-h dark period after the injection at 1800. * P Ͻ 0.05 vs. vehicle treatment.
sion of the inducible NO synthase, a rate-limiting enzyme for the production of NO (1, 31) . IL-4 (1, 20, 29, 32) and IL-10 (12, 15, 28, 57) also have these properties.
The present study also shows that injections of IL-13 and TGF-␤1 at dark onset are less effective than injections in the light period. We also reported that IL-4 and IL-10 had no inhibitory effects after dark-onset administration (26, 27) . Normally, IL-1␤ mRNA and TNF-␣ mRNA levels are lowest at dark onset, hence their productions at that time are likely low (17, 48) . Therefore, it is possible that the inhibitory effects of IL-13 or TGF-␤1 on IL-1␤ and TNF-␣ production may be less potent during the dark period. The onset of inhibitory effects on NREMS induced by IL-13 and TGF-␤1 is shorter than that observed in IL-4 and IL-10. The sleep-inhibitory effects of IL-4 and IL-10 are not manifested until 8-10 h after their administration (26, 27) . There are several possibilities for this difference. For example, it is possible that the times for diffusion of these inhibitory cytokines to effective sites can be different, because the location of these sites are still obscure. As another possibility, it may due to the stimulation of production of sleep-inhibitory substances such as receptor antagonists or soluble receptors for IL-1␤ and TNF-␣ by inhibitory cytokines. Administration of substances that bind IL-1 or TNF rapidly, such as antibodies and soluble receptors for IL-1␤ (36, 51) and TNF-␣ (50, 52, 53, 57) , inhibit NREMS within the first postinjection hour. Thus, if the ability of IL-13 or TGF-␤1 to induce production of these inhibitory substances is relatively rapid, then the latency for NREMS inhibitory effects could be shorter. Although the time course for this effect is unclear, IL-13 promotes the production of the IL-1 type II receptor, a decoy receptor (4), as well as the IL-1 receptor antagonist (9, 33, 59, 61) . TGF-␤ can also antagonize the effects of IL-1␤ by increasing the expression of the IL-1 receptor antagonist (58) as well as decreasing cell surface expression of IL-1 receptors (11, 44) . It is likely that the NREMS inhibitory effects of IL-13 and TGF-␤1 result from one or more of these mechanisms.
Although the present study did not show clear dosedependent inhibition of REMS, IL-13 slightly inhibited REMS. It is thought that sleep-regulatory mechanisms of REMS are different from those of NREMS. In cats, microinjection of NO synthase inhibitors into the pedunculopontine tegmental area reduces REMS as well as NREMS (8) . Therefore, brain stem NO ergic mechanisms could be implicated in the inhibitory effect of REMS by IL-13. Although we did not show any inhibitory effect for REMS by TGF-␤1, it is possible that the doses used in this study were insufficient to reveal a REMS-inhibitory effect; as mentioned above, TGF-␤1 also inhibits NO production. We previously reported that IL-4 and IL-10 inhibited REMS only in the highest doses used (26, 27) . These results suggest that the doses of inhibitory cytokines required for REMS inhibition are higher than those needed for NREMS inhibition.
In the present study, neither IL-13 nor TGF-␤1 affected EEG SWA. Previously, we reported that IL-4 and IL-10 also did not affect EEG SWA (26, 27) . Therefore, we can conclude that those anti-inflammatory cytokines tested thus far do not change EEG SWA in the doses that reduce NREMS. EEG SWA reflects the intensity of NREMS under many conditions (41) . For example, EEG SWA is markedly increased during the deep sleep occurring after sleep deprivation (42) . IL-1␤ and TNF-␣ are involved in this effect because sleep deprivation-enhanced EEG SWA is attenuated if animals are pretreated with inhibitors if IL-1 or TNF (37, 49, 53) . The reason why IL-4, IL-10, IL-13, or TGF-␤1 does not inhibit spontaneous EEG SWA remains unclear. However, the mechanisms responsible for EEG SWA are different from those responsible for NREMS, Values are means Ϯ SE. The number and length of the episodes were determined using a computer program with the criterion that each episode lasted at least 30 s. Light period data include initial 9 h data after the injection at 0900 or 11 h data following 12-h dark period after the injection at 1800. * P Ͻ 0.05 vs. vehicle treatment.
and thus it is reasonable to expect that these parameters can vary independently in some experimental conditions. For example, neurotrophin 1 and 2 promote NREMS but slightly decrease EEG SWA (25, 55) . Benzodiazepine hypnotics promote NREMS with decreases in EEG SWA. A benzodiazepine-receptor antagonist antagonizes drug-induced NREMS but does not antagonize the effect on EEG SWA (reviewed in Ref. 2) . The diurnal rhythms of NREMS in rats allowed food intake only during daylight hour shifts to one characterized by more NREMS during the dark than during the day; the rhythms of EEG SWA are not changed by restricted food intake (45) . Furthermore, it is also possible that the mechanisms responsible for duration of NREMS and EEG SWA may have different thresholds for the inhibitory effects of IL-13 and TGF-␤1.
IL-13 and TGF-␤1 failed to affect Tbr. These data are also consistent with those obtained after IL-4 and IL-10 treatment (26, 27) . Tbr is coupled to sleep states, but there are many conditions in which they are not tightly linked. For example, antipyretics antagonize IL-1-induced fever, but not sleep responses. In contrast, inhibitors of NO synthase block IL-1␤-induced sleep response, but not fevers (reviewed in Ref. 24) . The lack of effect of IL-13 and TGF-␤1 on Tbr at the doses that inhibit NREMS suggests that proinflammatory cytokines may have little effect in the regulation of normal body temperature.
The physiological functions of IL-13 in peripheral tissue have been studied; however, the function of IL-13 in the CNS has not yet been elucidated. TGF-␤1 is involved in cell growth, differentiation, adhesion, and proliferation in the CNS; however, it is expressed mainly in pathological conditions during adulthood (reviewed in Ref. 16 ). Therefore, we cannot conclude that these cytokines are involved in physiological sleep regulation. However, current data support the hypothesis that the cytokine network in the brain plays an important role in physiological sleep regulation.
